We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Pro-Lab Diagnostics Releases Top Quality C. Difficile GDH Immunoassay

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Pro-Lab Diagnostics has launched a high quality immunoassay for rapid and accurate screening of patients with suspected Clostridium difficile infection.

The Prolisa™ C. difficile GDH (glutamate dehydrogenase) EIA achieves excellent sensitivity and specificity thanks to a mouse monoclonal GDH antibody, and offers a high negative predictive value to quickly and easily rule out C. difficile infection.

Many recent studies have demonstrated that C. difficile infection can be identified more efficiently and economically by initially screening for GDH, rather than by testing for toxins alone.

Mark Reed, General Manager of Pro-Lab Diagnostics, explained: “Screening for GDH as a marker present in toxigenic and non-toxigenic strains of C. difficile, followed by tests for toxin A or toxin B on GDH-positive samples, is an easy, quick and cost-effective way to test for C. difficile infection, as several UK customers are already finding.”

Supported by Pro-Lab Diagnostics’ knowledgeable and friendly team of experts, the Prolisa C. difficile GDH EIA is a manual immunoassay, available in a 96-well test size, that has also been optimized and validated for the most widely used automated platforms.

Reagents are supplied in larger volumes as standard, to accommodate automated systems and provide more flexibility, and are also available separately, with comprehensive lot-to-lot compatibility.